(Ivanhoe Newswire )– Regulation of DNA may be causing a disease that isn’t hardwired. Acute myeloid leukemia is associated with various genetic changes. Some of those changes are epigenetic, meaning the sequence of genes in the DNA is not altered, but chemical variances alter the way genes are expressed.

 

A new study shows that targeting the balance of two DNA-binding proteins that regulate transcription, C/EBPg and C/EBPa, could provide a new therapeutic approach in the treatment of AML.

 

Researchers at Beth Israel Deaconess Medical Center found that C/EBPg was highly expressed in AML samples with an epigenetically silenced C/EBPa gene. The team, led by Daniel Tenen, found that by blocking the chemical modification of C/EBPA, they could reduce C/EPG and restore normal myeloid blood cells.

 

Source: Journal of Clinical Investigation

 

Want to be the FIRST TO KNOW?

Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.